دورية أكاديمية
Cervical cancer immune infiltration microenvironment identification, construction of immune scores, assisting patient prognosis and immunotherapy.
| العنوان: | Cervical cancer immune infiltration microenvironment identification, construction of immune scores, assisting patient prognosis and immunotherapy. |
|---|---|
| المؤلفون: | Yao S; Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, Hubei, China.; Hubei Cancer Clinical Study Center, Wuhan, Hubei, China., Zhao L; Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macau, Macau SAR, China.; Ministry of Education (MoE) Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau, Macau SAR, China., Chen S; Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China., Wang H; Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, Hubei, China.; Hubei Cancer Clinical Study Center, Wuhan, Hubei, China., Gao Y; Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, Hubei, China.; Hubei Cancer Clinical Study Center, Wuhan, Hubei, China., Shao NY; Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macau, Macau SAR, China.; Ministry of Education (MoE) Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau, Macau SAR, China., Dai M; Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, Hubei, China.; Hubei Cancer Clinical Study Center, Wuhan, Hubei, China., Cai H; Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.; Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, Hubei, China.; Hubei Cancer Clinical Study Center, Wuhan, Hubei, China. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Mar 10; Vol. 14, pp. 1135657. Date of Electronic Publication: 2023 Mar 10 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Uterine Cervical Neoplasms*/genetics , Uterine Cervical Neoplasms*/therapy, Humans ; Female ; Immunotherapy ; Prognosis ; Multigene Family ; Cell Proliferation ; Tumor Microenvironment/genetics |
| مستخلص: | Background: The immune microenvironment is of great significance in cervical cancer. However, there is still a lack of systematic research on the immune infiltration environment of cervical cancer. Methods: We obtained cervical cancer transcriptome data and clinical information from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases, evaluated the immune microenvironment of cervical cancer, determined immune subsets, constructed an immune cell infiltration scoring system, screened key immune-related genes, and performed single-cell data analysis and cell function analysis of key genes. Results: We combined the TCGA and GEO data sets and obtained three different immune cell populations. We obtained two gene clusters, extracted 119 differential genes, and established an immune cell infiltration (ICI) scoring system. Finally, three key genes, IL1B, CST7, and ITGA5, were identified, and single-cell sequencing data were mined to distribute these key genes in different cell types. By up-regulating CST7 and down-regulating IL1B and ITGA5, cervical cancer cells' proliferation ability and invasion ability were successfully reduced. Conclusion: We conducted a comprehensive assessment of the state of the tumor immune microenvironment in cervical cancer, constructed the ICI scoring system, and identified the ICI scoring system as a potential indicator of susceptibility to immunotherapy for cervical cancer, identifying key genes suggesting that IL1B, CST7, and ITGA5 play an essential role in cervical cancer. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Yao, Zhao, Chen, Wang, Gao, Shao, Dai and Cai.) |
| References: | Lancet Oncol. 2020 Oct;21(10):1353-1365. (PMID: 32919526) Cell. 2021 Jun 24;184(13):3573-3587.e29. (PMID: 34062119) Gynecol Oncol. 2013 Nov;131(2):480-8. (PMID: 23994536) Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:59-72. (PMID: 29108943) Cancer Treat Rev. 2017 Sep;59:109-116. (PMID: 28800469) Expert Rev Anticancer Ther. 2009 Jul;9(7):895-903. (PMID: 19589029) Cleve Clin J Med. 2019 Mar;86(3):173-178. (PMID: 30849035) Cancer Genet. 2020 Oct;248-249:25-30. (PMID: 32987255) Drug Des Devel Ther. 2016 Jun 07;10:1885-95. (PMID: 27354763) J Immunol. 2014 Jun 15;192(12):5451-8. (PMID: 24907378) Front Immunol. 2022 Nov 03;13:994828. (PMID: 36405728) Cancer Radiother. 2019 Oct;23(6-7):737-744. (PMID: 31455591) Front Cell Dev Biol. 2021 Sep 28;9:732786. (PMID: 34650978) Biomed Res Int. 2021 Dec 06;2021:4532438. (PMID: 34917682) Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):396-412. (PMID: 32942005) Curr Treat Options Oncol. 2020 Oct 6;21(12):95. (PMID: 33025260) J Natl Med Assoc. 2020 Apr;112(2):229-232. (PMID: 32278478) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) J Gynecol Oncol. 2016 Jul;27(4):e43. (PMID: 27171673) Aktuelle Urol. 2010 Jan;41 Suppl 1:S34-40. (PMID: 20094950) Histopathology. 2020 Jan;76(1):157-170. (PMID: 31846530) Curr Cancer Drug Targets. 2013 Feb;13(2):205-20. (PMID: 23259831) Oncoimmunology. 2021 Jun 12;10(1):1936391. (PMID: 34178428) J Clin Invest. 2021 Jul 15;131(14):. (PMID: 34138753) PLoS One. 2014 Dec 08;9(12):e114536. (PMID: 25486122) Gynecol Oncol. 2012 Aug;126(2):291-303. (PMID: 22504292) J Exp Clin Cancer Res. 2022 Feb 8;41(1):54. (PMID: 35135586) Curr Probl Cancer. 2018 Mar - Apr;42(2):175-188. (PMID: 29776594) Mol Pain. 2016 Jun 15;12:. (PMID: 27306412) Clin Immunol. 2020 Oct;219:108551. (PMID: 32739413) Oncogene. 2020 Aug;39(34):5633-5648. (PMID: 32661323) Nat Methods. 2017 Oct;14(10):979-982. (PMID: 28825705) Nat Commun. 2021 Feb 17;12(1):1088. (PMID: 33597522) J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32217756) Expert Rev Anticancer Ther. 2016;16(1):83-98. (PMID: 26568261) Front Med. 2019 Aug;13(4):438-450. (PMID: 30826965) Int Immunol. 2018 Sep 25;30(10):445-454. (PMID: 29939325) Blood. 1986 Aug;68(2):493-7. (PMID: 3730612) Mol Ther Nucleic Acids. 2021 Apr 02;24:682-694. (PMID: 33996252) Neoplasma. 2014;61(4):481-90. (PMID: 24712845) Springerplus. 2013 May 31;2(1):249. (PMID: 23762817) J Reprod Immunol. 2020 Jun;139:103115. (PMID: 32199196) Clin Transl Oncol. 2020 Dec;22(12):2196-2205. (PMID: 32445035) J Immunother Cancer. 2021 Jul;9(7):. (PMID: 34261702) Nat Rev Clin Oncol. 2016 Mar;13(3):143-58. (PMID: 26598942) J Obstet Gynaecol. 2020 Jul;40(5):602-608. (PMID: 31500479) J Cell Physiol. 2018 Sep;233(9):6425-6440. (PMID: 29319160) Oncogene. 2021 Feb;40(7):1284-1299. (PMID: 33420367) Viruses. 2017 Sep 12;9(9):. (PMID: 28895886) Papillomavirus Res. 2019 Dec;8:100170. (PMID: 31176807) Ann Oncol. 2019 Jan 1;30(1):44-56. (PMID: 30395155) Neuroscience. 2016 Mar 24;318:114-21. (PMID: 26794594) Clin Oncol (R Coll Radiol). 2019 Dec;31(12):834-843. (PMID: 31331818) Cancer Res. 2021 Dec 1;81(23):6018-6028. (PMID: 34593523) Lancet Glob Health. 2020 Feb;8(2):e191-e203. (PMID: 31812369) Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369. (PMID: 30545915) Curr Oncol Rep. 2018 Apr 2;20(5):40. (PMID: 29611060) BMC Cancer. 2019 May 28;19(1):506. (PMID: 31138229) Theranostics. 2017 Aug 22;7(14):3585-3594. (PMID: 28912897) Anticancer Agents Med Chem. 2014 Feb;14(2):265-79. (PMID: 24237218) Tumour Biol. 2014 Feb;35(2):1605-8. (PMID: 24122201) Ann Oncol. 2019 Sep 1;30(9):1496-1506. (PMID: 31268125) Cancer Immunol Immunother. 2020 Dec;69(12):2651-2664. (PMID: 32607768) Nat Commun. 2013;4:2612. (PMID: 24113773) Nat Immunol. 2013 Oct;14(10):1014-22. (PMID: 24048123) J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32238472) J Urol. 2015 May;193(5):1676-83. (PMID: 25572034) Nat Genet. 2019 Feb;51(2):202-206. (PMID: 30643254) J Clin Oncol. 2015 May 10;33(14):1543-50. (PMID: 25823737) World J Surg Oncol. 2022 Jan 4;20(1):2. (PMID: 34980144) Front Immunol. 2019 May 24;10:1084. (PMID: 31178859) Br J Cancer. 2021 Jan;124(2):414-424. (PMID: 33087896) Nat Rev Drug Discov. 2019 Mar;18(3):175-196. (PMID: 30622344) |
| فهرسة مساهمة: | Keywords: ICI score; TMB; cervical cancer; immune infiltration; immune microenvironment |
| تواريخ الأحداث: | Date Created: 20230327 Date Completed: 20230328 Latest Revision: 20230328 |
| رمز التحديث: | 20230329 |
| مُعرف محوري في PubMed: | PMC10037308 |
| DOI: | 10.3389/fimmu.2023.1135657 |
| PMID: | 36969161 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1135657 |